2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Revenue | $224M | $236M | $272M | $249M | $233M |
Cost of Revenue | $10M | $9.6M | $0 | $11M | $0 |
Gross Profit | $214M | $226M | $272M | $238M | $233M |
Gross Profit % | 96% | 96% | 100% | 95% | 100% |
R&D Expenses | $0 | $0 | $0 | $0 | $0 |
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Net Income | $42M | $99M | $101M | $80M | $62M |
Dep. & Amort. | $11M | $16M | $15M | $9.2M | $6.5M |
Def. Tax | $24M | -$41M | $33M | $0 | $0 |
Stock Comp. | $2.5M | $2.4M | $2.6M | $2.7M | $0 |
Chg. in WC | -$12M | $9.3M | $22M | $21M | $0 |
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Cash | $392M | $609M | $352M | $302M | $305M |
ST Investments | $754M | $911M | $854M | $866M | $0 |
Cash & ST Inv. | $1.1B | $1.5B | $1.2B | $1.2B | $305M |
Receivables | $440M | $499M | $613M | $627M | $0 |
Inventory | -$455M | -$666M | -$423M | $0 | $0 |
HAFC reported strong Q1 2025 results with net income of $17.7 million ($0.58 per diluted share), up 17% and 16% respectively year-over-year, and continued net interest margin expansion to 3.02%.
Total loans grew to $6.28 billion (up 0.5% quarter-over-quarter), with solid production across all categories; deposits increased 3% driven by new commercial accounts and branch contributions, with non-interest bearing deposits at 31.2% of total.
Asset quality remained stable: allowance for credit losses held at 1.12% of loans, nonperforming assets rose slightly due to a syndicated CRE office loan, but overall credit metrics were flat; office CRE maturities in 2025 (~$200M) are not expected to present issues.
Operating expenses were well managed, resulting in an efficiency ratio of 55.7% (best since Q4 2023); noninterest income rose 5% primarily from SBA loan sales, and tangible book value per share increased 2.6% to $24.49.
Forward-looking: Management expects low-to-mid single digit loan growth for 2025, continued focus on C&I expansion, further margin expansion at a slower pace, disciplined expense management (3-4% salary/benefit increase in Q2), and ongoing share repurchases subject to board approval.